Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology
Disease Category: Bipolar Disorders
Trial Information
Allopurinol Add-on Treatment for Refractory Mania: A Double-Blind, Placebo-Controlled Augmentation Study with Allopurinol for Treatment Resistant Mania
Bipolar disorder is a severe mental disorder with episodes of
mania and depression. Current medications can have significant side
effects, high costs, and require blood monitoring. The purpose of
this study is to test the safety and effectiveness of allopurinol
in combination with lithium, volproic acid, or carbamazepine for
treatment-resistant bipolar mania and mixed mania. Allopurinol has
been approved by the FDA as a treatment for calcium renal calculus,
gout, and hyperunicemia but it has not been approved for use in
treatment-resistant bipolar and mixed mania.
This placebo-controlled, double-blind study will involve 6 study
visits over 7 weeks including a screening and baseline visit.
During the screening visit a review of medical and psychiatric
history as well as psychiatric assessments will be completed. A
physical exam will be administered along with a blood draw and
urine sample. At the baseline visit questionnaires concerning mood,
disability, medications, and side effects will be completed. Vitals
(blood pressure, heart rate, temperature and weight) will be
measured and participants will be assigned to either the medication
study group which will receive allopurinol or to the study group
which will receive a placebo. At the 4 study visits, participants
will be asked to complete questionnaires and vitals will be taken.
In addition, blood will be drawn at the week 2 visit and a blood
draw, urine sample collection and exit physical exam will be
conducted at the week 6 (final) study visit.
Participants will continue taking their current medications at
current doses throughout the study. Participants will be monitored
by a study doctor throughout the research study. Participants will
receive $40 for each research study visit with a total of $240 for
completion of the entire study.
Patient Inclusion Criteria:
- Subjects must meet DSM-IV criteria for bipolar disorder, most
recent episode manic or mixed, at the time of screening confirmed
by the Mini International Neuropsychiatric Interview (MINI)
- Subjects must be taking medication for bipolar disorder for at
least 4 weeks prior to study entry
- 18-70 years of age
Patient Exclusion Criteria:
- Subjects with a serious, unstable medical illness (such as
cardiovascular, respiratory, neurologic, hematologic, renal,
hepatic, endocrine, immunologic, or other systemic illness), a
history of cerbrovascular disease, uncontrolled diabetes mellitus
or AIDS. Subjects with chronic illness must be stable and otherwise
physically healthy on the basis of a physical examination, medical
history, electrocardiogram and the results of blood biochemistry,
hematology tests and a urinalysis.
- Subjects with a history of substance abuse or dependence
(excluding nicotine and caffeine) according to DSM-IV criteria
within last 4 weeks.
- Subjects who have been intoxicated with alcohol or illicit
drugs within 3 days prior to baseline
- Subjects with severe mood symptoms requiring
hospitalization
- Subjects taking dopamine agonists and/or anti-psychotics
- Subjects with gout or renal insufficiency
- Subjects taking azathioprine, mercaptopurine, apalcillin,
and/or amoxicillin
- Subjects with a history of severe pre-existing gastrointestinal
narrowing or inability to swallow oral study medication whole with
the aid of water
- Female subjects who are pregnant or nursing
- Subjects who have received an experimental drug or used an
experimental medical device within 1 month of screening
For more information,
Lisa Glassman, Study Cooridnator
Cedars-Sinai Medical Center
8730 Alden Dr. Room E123
Los Angeles, CA 90048
Phone: 310-423-6515
Fax: 310-423-0888
EMail: glassmanl@cshs.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.